AYTU BIOPHARMA, INC
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
AYTU$1.81+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, June 30, 2025 | 8,976,913 | $1 | $352,500 | $(333,535) | $18,966 |
| Stock-based compensation expense | — | — | 114 | — | 114 |
| Issuance of common stock from exercise of warrants | 935,000 | — | 2,126 | — | 2,126 |
| Net income | — | — | — | 1,965 | 1,965 |
| Balances, September 30, 2025 | 9,911,913 | $1 | $354,740 | $(331,570) | $23,171 |
| Additional · Total | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balances, June 30, 2024 | 5,972,638 | $1 | $347,688 | $(319,973) | $27,716 |
| Stock-based compensation expense | 564 | — | 173 | — | 173 |
| Issuance of common stock from exercise of warrants | 176,000 | — | 463 | — | 463 |
| Net income | — | — | — | 1,474 | 1,474 |
| Balances, September 30, 2024 | 6,149,202 | $1 | $348,324 | $(318,499) | $29,826 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.